FOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal CancersFOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal Cancers

In patients with KRAS exon 2 wild-type metastatic colorectal cancer (MCC) who received first-line FOLFIRI (fluorouracil, folinic acid and irinotecan), adding cetuximab rather than bevacizumab yielded longer overall survival. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news